India logs in 92,071 new COVID cases, recovery rate rises to 78%

While the virus has infected a total of 48,46,427 people, 79,722 have died so far

COVID-19, COVID, corona
Representative photo: PTI

India on Monday (September 14) recorded 92,071 new COVID-19 infections, with the total tally mounting to 48,46,427 while the death toll reached 79,722 with 1,136 more people succumbing to the infection in 24 hours.

According to Home Ministry data, 37.8 lakh people have recuperated so far, taking the national recovery rate to 78 per cent on Monday.

The COVID-19 case fatality rate due to the coronavirus infection has further dropped to 1.64 per cent. There are 9,86,598 active cases of COVID-19 in the country, while 37,80,107 people have recuperated, the data stated.

Monday’s count is a relief from the spike in cases seen in the past few days when single-day cases remained above the 94,000-mark.


India’s COVID-19 tally had crossed the 20-lakh mark on August 7, 30 lakh on August 23 and it went past 40 lakh on September 5. According to the ICMR, a cumulative total of 5,72,39,428 samples have been tested up to September 13 with 9,78,500 samples being tested on Sunday.

The Monsoon Session of Parliament began on Monday, amid strict COVID protocol like staggered sittings of sessions and use of poly-carbon sheets in the Houses.

Announcing on Sunday that a COVID-19 vaccine may be ready by the first quarter of 2021 Union Health Minister Harsh Vardhan said he is ready to receive it first if people have a trust deficit in its efficacy.

Related news: Will take 1st dosage of COVID vaccine if there is trust deficit: Harsh Vardhan

Healthcare workers, senior citizens and people with co-morbidities will be given priority in the administration of the vaccine when it is out, he said.

At least three vaccines developed by Bharat Biotech, Zydus Cadilla and Oxford-AstraZeneca are in different phases of trials in India. Recently, the human trial of the Oxford-AstraZeneca vaccine – conducted by Serum Institute in India- was paused on the direction of the drug regulator after the parent company halted it following an unexplained illness in one of the volunteers.

Related news: Chyawanaprash to pranayama: Centre’s SOP for COVID-cured wraps it all